PCI Biotech: Employee share option scheme
Oslo, 06 October 2020
Here is the original post:
PCI Biotech: Employee share option scheme
Yearly Archives: 2020
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
VANCOUVER, British Columbia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based biopharmaceutical company focused on skin health and healthy ageing, is pleased to announce that one of its topical drugs produced significant, and dose dependent inhibitory effects in a well established mouse model of psoriasis. Psoriasis is a chronic inflammatory skin disease often linked to depression and a decreased quality of life. The global psoriasis treatment market is projected to reach USD $37 billion by 2026. These results come on the heels of a successful preclinical study in atopic dermatitis earlier this year using the same drug.
Read more from the original source:
Derm-Biome Pharmaceuticals, Inc. Reports Positive Results from a Preclinical Study In Psoriasis
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov
Ljubljana, Slovenia, Oct. 06, 2020 (GLOBE NEWSWIRE) -- Rafarma Pharmaceuticals, Inc. OTC:(RAFA) is pleased to announce approval of Ilya Shpurov receiving the majority of Preferred B shares, conferring voting control of the company, toward the combination of its acquisition by R. & D. BIOCOGENCY LABORATORIES Group of Companies. The issuance of restricted preferred shares does not create any dilution of common shares.
See the original post here:
Rafarma Approves Issuance of Majority of Voting Shares to Board Chairman Ilya Shpurov
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch…
·BYFAVO expected to be commercially available in the US before the end of the year This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
See the article here:
Acacia Pharma announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch...
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
Issued Patent is the First Covering Firdapse® Issued Patent is the First Covering Firdapse®
Go here to read the rest:
Catalyst Pharmaceuticals Announces Issuance of U.S. Patent for Firdapse®
Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13
Conference Call and Webcast Scheduled for October 13, 2020, 4:30 pm ET
Read more:
Enzo Biochem to Report Fourth Quarter and Fiscal Year 2020 Financial Results on Tuesday, October 13
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
Steven H. Rouhandeh Appointed as Chairman of the Board of Directors
See the original post:
Abeona Therapeutics’ Board of Directors Forms Special Committee to Oversee Operations, Develop Strategic Direction and Leadership Plan
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network
With the new contract, PRA will assist Biomedical Advanced Research and Development Authority (BARDA) in the development of medical countermeasures for public health
Read the original post:
PRA Health Sciences selected by BARDA to be a member of its exclusive Clinical Studies Network